[1]
Chowdhury S, Ghosh T, Goel A, Singh AK, Kumar A, Wig N. Utility of walk tests in progression of mild COVID-19 infection at a tertiary hospital in North India. Recent Adv Antiinfect Drug Discov. 2022; Jun 30.
[http://dx.doi.org/10.2174/2772434417666220630112737]
[http://dx.doi.org/10.2174/2772434417666220630112737]
[2]
Kumar A, Mishra M, Banerjee S, et al. Clinical profile, risk factors, and therapeutic outcome of cavitating fungal pneumonia coinfection in COVID-19 patients: A retrospective analysis. Recent Adv Antiinfect Drug Discov 2022; Jul 20.
[http://dx.doi.org/10.2174/2772434417666220720122042]
[http://dx.doi.org/10.2174/2772434417666220720122042]
[3]
ISARIC Clinical Characterisation Group, et al. Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19: An observational cohort. Elife. 2021; Nov 23;10:e70970.
[http://dx.doi.org/10.7554/eLife.70970]
[http://dx.doi.org/10.7554/eLife.70970]
[4]
Kapoor M, Singh BO, Panda PK, Dhanger P, Kataria A. Comparing India's second COVID wave with the first wave - a single-center experience. Recent Adv Antiinfect Drug Discov. 2022; Jun 28.
[http://dx.doi.org/10.2174/2772434417666220628153110]
[http://dx.doi.org/10.2174/2772434417666220628153110]
Related Books
Frontiers in Clinical Drug Research: Anti-Infectives
Frontiers in Anti-Infective Drug Discovery
Coronaviruses
Moving From COVID-19 Mathematical Models to Vaccine Design: Theory, Practice and Experiences
COVID-19: Effects in Comorbidities and Special Populations
An Update on SARS-CoV-2: Damage-response Framework, Potential Therapeutic Avenues and the Impact of Nanotechnology on COVID-19 Therapy
An Epidemiological Update on COVID -19
Frontiers in Clinical Drug Research: Anti-Infectives
Frontiers in Anti-infective Agents
Coronavirus Disease-19 (COVID-19): A Perspective of New Scenario
